Prothipendyl

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Summary

Prothipendyl is a neuroleptic agent indicated in the treatment of restlessness and agitation in patients with underlying psychiatric conditions.

Generic Name
Prothipendyl
DrugBank Accession Number
DB12958
Background

Prothipendyl has been used in trials studying the treatment of Dementia, Depression, Schizophrenia, Anxiety Disorders, and Psychosomatic Disorders.

Type
Small Molecule
Groups
Investigational
Structure
Thumb
Weight
Average: 285.41
Monoisotopic: 285.129968798
Chemical Formula
C16H19N3S
Synonyms
  • Prothipendyl
  • Prothipendylum
  • Protipendilo
External IDs
  • AY 56031
  • D 206
  • LG 206
  • MH 05101

Pharmacology

Indication

Not Available

Pharmacology
Reduce drug development failure rates
Build, train, & validate machine-learning models
with evidence-based and structured datasets.
See how
Build, train, & validate predictive machine-learning models with structured datasets.
See how
Associated Conditions
Contraindications & Blackbox Warnings
Contraindications
Avoid life-threatening adverse drug events
Improve clinical decision support with information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.
Learn more
Avoid life-threatening adverse drug events & improve clinical decision support.
Learn more
Pharmacodynamics

Not Available

Mechanism of action
Not Available
Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism
Not Available
Route of elimination

Not Available

Half-life

Not Available

Clearance

Not Available

Adverse Effects
Adverseeffects
Improve decision support & research outcomes
With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates.
Learn more
Improve decision support & research outcomes with our structured adverse effects data.
Learn more
Toxicity

Not Available

Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
1,2-BenzodiazepineThe risk or severity of adverse effects can be increased when 1,2-Benzodiazepine is combined with Prothipendyl.
AcetazolamideThe risk or severity of adverse effects can be increased when Acetazolamide is combined with Prothipendyl.
AcetophenazineThe risk or severity of adverse effects can be increased when Acetophenazine is combined with Prothipendyl.
AclidiniumProthipendyl may increase the central nervous system depressant (CNS depressant) activities of Aclidinium.
AgomelatineThe risk or severity of adverse effects can be increased when Agomelatine is combined with Prothipendyl.
AlfentanilThe risk or severity of adverse effects can be increased when Alfentanil is combined with Prothipendyl.
AlimemazineThe risk or severity of adverse effects can be increased when Alimemazine is combined with Prothipendyl.
AlmotriptanThe risk or severity of adverse effects can be increased when Almotriptan is combined with Prothipendyl.
AlosetronThe risk or severity of adverse effects can be increased when Alosetron is combined with Prothipendyl.
AlprazolamThe risk or severity of adverse effects can be increased when Alprazolam is combined with Prothipendyl.
Interactions
Identify potential medication risks
Easily compare up to 40 drugs with our drug interaction checker.
Get severity rating, description, and management advice.
Learn more
Food Interactions
Not Available

Products

Products2
Drug product information from 10+ global regions
Our datasets provide approved product information including:
dosage, form, labeller, route of administration, and marketing period.
Access now
Access drug product information from over 10 global regions.
Access now
Product Ingredients
IngredientUNIICASInChI Key
Prothipendyl hydrochloride7610629RVH1225-65-6CQJSAKJMCVSEGU-UHFFFAOYSA-N
Prothipendyl hydrochloride monohydrate9G1ILH80SA70145-94-7YATJECIBCQMRMY-UHFFFAOYSA-N
International/Other Brands
Dominal / Tumovan

Categories

ATC Codes
N05AX07 — Prothipendyl
Drug Categories
Chemical TaxonomyProvided by Classyfire
Description
This compound belongs to the class of organic compounds known as alkyldiarylamines. These are tertiary alkylarylamines having two aryl and one alkyl groups attached to the amino group.
Kingdom
Organic compounds
Super Class
Organic nitrogen compounds
Class
Organonitrogen compounds
Sub Class
Amines
Direct Parent
Alkyldiarylamines
Alternative Parents
Diarylthioethers / Benzothiazines / Pyridines and derivatives / Imidolactams / Benzenoids / 1,4-thiazines / Heteroaromatic compounds / Trialkylamines / Azacyclic compounds / Organopnictogen compounds
show 1 more
Substituents
Alkyldiarylamine / Aromatic heteropolycyclic compound / Aryl thioether / Azacycle / Benzenoid / Benzothiazine / Diarylthioether / Heteroaromatic compound / Hydrocarbon derivative / Imidolactam
show 6 more
Molecular Framework
Aromatic heteropolycyclic compounds
External Descriptors
Not Available
Affected organisms
Not Available

Chemical Identifiers

UNII
5O6VWA87VA
CAS number
303-69-5
InChI Key
JTTAUPUMOLRVRA-UHFFFAOYSA-N
InChI
InChI=1S/C16H19N3S/c1-18(2)11-6-12-19-13-7-3-4-8-14(13)20-15-9-5-10-17-16(15)19/h3-5,7-10H,6,11-12H2,1-2H3
IUPAC Name
dimethyl(3-{9-thia-2,4-diazatricyclo[8.4.0.0^{3,8}]tetradeca-1(14),3(8),4,6,10,12-hexaen-2-yl}propyl)amine
SMILES
CN(C)CCCN1C2=CC=CC=C2SC2=C1N=CC=C2

References

General References
  1. DIMDI Drug Product Information: Dominal (prothipendyl hydrochloride) for oral use [Link]
PubChem Compound
14670
PubChem Substance
347829098
ChemSpider
14002
RxNav
55244
ChEBI
135182
ChEMBL
CHEMBL2111030
ZINC
ZINC000000001996
Wikipedia
Prothipendyl

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
3TerminatedTreatmentAnxiety Disorders / Dementia / Depression / Psychosomatic Disorders / Schizophrenia1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
FormRouteStrength
SolutionOral50 mg/mL
Tablet, coatedOral40 MG
Tablet, film coatedOral
Tablet, film coatedOral80 MG
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.128 mg/mLALOGPS
logP3.53ALOGPS
logP3.31ChemAxon
logS-3.4ALOGPS
pKa (Strongest Basic)9.2ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count3ChemAxon
Hydrogen Donor Count0ChemAxon
Polar Surface Area19.37 Å2ChemAxon
Rotatable Bond Count4ChemAxon
Refractivity87.11 m3·mol-1ChemAxon
Polarizability32.44 Å3ChemAxon
Number of Rings3ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET Features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Drug created on October 21, 2016 01:35 / Updated on October 20, 2021 18:14